Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5967364/
https://www.ncbi.nlm.nih.gov/pubmed/29794072
http://dx.doi.org/10.1136/bmj.k2031
_version_ 1783325601414774784
collection PubMed
description
format Online
Article
Text
id pubmed-5967364
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BMJ Publishing Group Ltd.
record_format MEDLINE/PubMed
spelling pubmed-59673642018-05-31 Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis BMJ Research BMJ Publishing Group Ltd. 2018-05-21 /pmc/articles/PMC5967364/ /pubmed/29794072 http://dx.doi.org/10.1136/bmj.k2031 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Research
Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis
title Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis
title_full Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis
title_fullStr Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis
title_full_unstemmed Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis
title_short Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis
title_sort postmarket studies required by the us food and drug administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5967364/
https://www.ncbi.nlm.nih.gov/pubmed/29794072
http://dx.doi.org/10.1136/bmj.k2031

Ejemplares similares